Ipilimumab vs Omega-3-Carboxylic Acids
Ipilimumab vs Omega-3-Carboxylic Acids: Overview
This comparison examines the pharmacological differences between Ipilimumab and Omega-3-Carboxylic Acids.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Ipilimumab β 14.7 days.
Chemical Properties
Type: Ipilimumab β Antibody; Omega-3-Carboxylic Acids β Unknown.